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ABSTRACT
Unwinding duplex DNA is a critical processing step during replication, repair and 
transcription. Pif1 are highly conserved non-processive 5’->3’ DNA helicases with 
well-established roles in maintenance of yeast genome stability. However, the function 
of the sole member of Pif1 family in humans remains unclear. Human PIF1 is essential 
for tumour cell viability, particularly during replication stress, but is dispensable in 
non-cancerous cells and Pif1 deficient mice. Here we report that suppression of PIF1 
function slows replication fork rates and increases arrested forks during normal cycling 
conditions. Importantly, PIF1-dependent replication impediments impair S-phase 
progression and reduce proliferation rates of RAS oncogene-transformed fibroblasts, 
where replication fork slowing is exacerbated, but not parental, non-cancerous cells. 
Disrupted fork movement upon PIF1-depletion does not enhance double-stranded 
break formation or DNA damage responses but affects resumption of DNA synthesis 
after prolonged replication inhibitor exposure, accompanied by diminished new origin 
firing and mainly S-phase entry. Taken together, we characterised a functional role 
for human PIF1 in DNA replication that becomes important for cell growth under 
oncogenic stress. Given that oncogenes induce high levels of replication stress during 
the early stages of tumorigenesis, this function of PIF1 could become critical during 
cancer development.
INTRODUCTION
Human cells encode a number of helicases that 
catalyse the unwinding of DNA in a directionally specific 
manner. Several of these are essential for cell growth 
and survival whereas loss or mutation of others have 
been causally related to genetic disorders with cancer 
predisposition [1] including Blooms [2], Werners [3], 
Rothmund-Thomson [4] and Fanconi’s Anemia [5] 
syndromes. The highly conserved Pif1 proteins protect 
genome stability, by regulating telomere homeostasis [6], 
Okazaki fragment maturation [7], G-quadruplex 
DNA (G4-DNA) resolution [8, 9], replication through 
DNA-protein barriers and highly transcribed genes 
[10, 11] and, replication induced by DNA double-strand 
breaks (DBS) [12, 13]. However, it is unclear whether the 
above functions have been conserved in all proteins of the 
Pif1 family. A pronounced example is the distinct roles 
of the ScPif1 and ScRrm3 proteins in DNA replication of 
the yeast Saccharomyces cerevisiae genome [14–16]. This 
also reflects the fact that although Pif1 proteins perform 
multiple tasks in DNA metabolism, not all of them are 
essential for cell viability [14, 17, 18].
The human genome encodes a single PIF1 
gene. Its expression, via alternative splicing, gives 
rise to two transcriptional isoforms, translation of 
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which results in two protein isoforms with different 
subcellular localisation [19]. The major transcript, 
hPif1a, encodes a nuclear polypeptide of approximately 
70kDa [19–21]. The second transcript, hPif1b, encodes a 
polypeptide of approximately 75kDa, highly enriched in 
mitochondria [19]. A second mitochondrial polypeptide, 
approximately 45kDa, can be generated from the hPif1a, 
by downstream Alternative Translation Initiation [22]. 
It is worth mentioning that the presence, function and 
physiological significance of the two mitochondrial 
PIF1 isoforms remain unclear since they have not 
been conserved in mouse [17]. It is possible that their 
expression is limited and/or is restricted to specific human 
tissues since they have been identified only in the two 
above studies, respectively. For the purpose of clarity, we 
will further refer to 70kDa nuclear isoform, as the human 
PIF1 protein.
Concerning its biochemical properties and biological 
significance, human PIF1 shares common in vitro 
substrates with the yeast Pif1 proteins, having specificity 
for telomeric DNA [21], synthetic stalled DNA replication 
fork-like structures [23, 24], but mainly for G4-DNA [25]. 
We have shown [26] that siRNA-mediated PIF1-depletion 
results in a combination of apoptosis, reduced survival, 
hypersensitivity to therapeutic DNA replication inhibitors 
and defective cell cycle progression in several cancer 
cell lines independent of p53 status. Importantly, non-
cancerous cells did not show a similar response.
We reasoned that PIF1 could affect DNA replication 
in a way that becomes particularly critical only during 
replication stress experienced by cancer cells. Given that 
oncogene expression induces replication stress during early 
stages of tumorigenesis [27, 28] we aimed to investigate 
whether specific oncogene transformations of non-
cancerous cells could trigger PIF1-dependent mechanism(s) 
of DNA replication progression and recovery, ensuring cell 
growth and proliferation. We found that PIF1 functions to 
maintain undisrupted DNA replication fork progression 
during normal cycling conditions and to support resumption 
of DNA synthesis after prolonged S-phase arrest. The 
dependence of DNA replication on PIF1 function increases 
under oncogene overexpression.
RESULTS
PIF1-depletion impairs genome-wide DNA 
replication progression during unperturbed 
conditions
For our experimental system, we over-expressed 
the mutated form of the proto-oncogene RAS, H-RASG12V, 
commonly found in human tumours [29], in immortalized 
MRC5SV2 human fibroblasts. RAS stable protein 
expression was confirmed by Western blot analysis 
(Fig. 1A). Suppression of PIF1 function was performed 
by siRNA-mediated depletions. Due to the limited levels 
of the endogenous PIF1 protein that make its detection 
by immunoblotting difficult, as we and others have shown 
[20, 26], the efficiency of the siRNA treatments was 
determined by quantitative PCR (qPCR) (Fig. 1B and 
Supplementary Information Text and Fig. S1A-E).
To test our hypothesis, we applied genome-
wide DNA-fibre analysis [30]. In a double-label assay, 
parental and RAS-oncogene-transformed fibroblasts, 
after transfection with control or PIF1 siRNAs, were 
pulse-labelled with the thymidine analogues 5-Chloro-
2′-deoxyuridine (CIdU) and 5-Iodo-2′-deoxyuridine 
(IdU) (Fig. 1C), and the length of labelled tracks on DNA 
spreads was measured by immunofluorescence analysis. 
Fork rates were assessed from ongoing replication 
structures (Fig. 1D). During an unperturbed cell cycle, 
replication elongation rates were slower in parental 
fibroblasts, after PIF1-depletion: a significant shift of 
the entire distribution of fork rates was observed in PIF1 
knockdowns relative to control, leftwards to slower rates 
(Fig. 1E). This was more pronounced during the second 
pulse, where the average fork speed of control siRNA 
treated cells was reduced from 0.91kb/min to 0.65kb/min 
(p=0.017) after PIF1 siRNA treatment.
Fork rate slowing upon PIF1-depletion was 
greatly exacerbated in RAS-transformed fibroblasts, 
where the average rate of replication fork progression 
diminished by about half, relative to control, during 
both pulses [%percentage reduction of fork rates: 42.17 
(p=0.007) and 53.42 (p=0.016) in CIdU and IdU tracks, 
respectively, (Fig. 1F)]. This exacerbation was specific 
to RAS overexpression since simultaneous treatment of 
RAS-transformed fibroblasts with HRAS and control or 
PIF1 siRNAs restored fork rates to parental levels (Fig. 1G). 
In particular, the average fork rate of CIdU tracks in 
RAS-transformed cells co-treated with control and HRAS 
siRNAs was 1.03kb/min relative to 1.05kb/min (p=0.275) 
in control siRNA-treated parental cells, while co-treatment 
of RAS-transformed cells with PIF1 and HRAS siRNAs 
produced a rate of 0.88kb/min vs 0.94kb/min (p=0.175) 
in PIF1 siRNA-transfected parental cells. Similarly, 
measurements of IdU tracks showed that co-treatment 
with control and HRAS siRNAs in RAS-transformed 
cells leads to an average fork speed of 0.77kb/min relative 
to 0.91kb/min (p=0.216) in control siRNA parental cells, 
while co-treatment of RAS-transformed cells with PIF1 
and HRAS siRNAs resulted to 0.68 vs 0.65 (p=0.487) 
in PIF1 siRNA parental cells. Additionally, similar 
results were obtained with a second clonal derivative of 
MRC5SV2 expressing RAS (clone 3), where the effects 
of PIF1 depletion on replication fork movement were 
studied after deconvolution of the siRNA pools used 
above (Supplementary Fig. S2A-C and S3A-D). In all 
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Figure 1: PIF1 depletion slows DNA replication fork rates under normal cycling conditions. (A) Western blot analysis of 
RAS expression in parental and H-RASG12V-transformed (clone 2) MRC5SV2 cells after indicated siRNA treatments. ϐ-actin levels served 
as loading controls, (B) Quantitative RT-PCR analysis of total PIF1mRNA, (C) Labelling protocol of parental and MRC5SV2-RAS cells 
after indicated treatment, (D) Representative images (scale bars=20μm) of replication tracks. White arrows marked with (i) and (ii) indicate 
single forks containing tracks from the 1st and 2nd pulses (red-green) and, bidirectional forks (green-red-green) generated in the 1st pulse, 
respectively, (E-G) Distribution of fork rates during CIdU and IdU pulses is shown in left and right panels, respectively. Fork rates were 
calculated as the length of the labelled track divided by the time of the pulse. Data bars present the mean of three independent experiments 
and error bars represent SD in B and SEM in panels E-G. In fork rate distributions, the total mean and SD of the three repeats are also 
shown, as well as p values of Student’s t test. The exact numbers (n) for each experiment are listed as well.
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the above assays, we observed a greater effect of siRNA 
treatments on fork rate slowing during the second pulse 
relative to the first one. A reported explanation [31] for 
this is that by measuring only double-labelled structures 
(red-green and, green-red-green), we exclude all the 
pausing events that can occur during the first pulse and 
lead to unilabelled tracks (only red). However, structures 
with stalled/termination events upon the second pulse are 
included because they were already labelled from the first 
pulse [31].
To examine whether slow fork speed was 
associated with further changes of DNA replication, in 
the above assays we measured inter-origin distances as 
an indication of new origin activation (Fig. 2A-C). We 
found that origin-to-origin distances were reduced in RAS 
transformed fibroblasts relative to parental cells (average 
distance: 47.45μm and 59.8μm (p=0.002) in MRC5SV2-
RAS and MRC5SV2 cells, respectively), in accord to the 
previously reported aberrant replication initiation during 
oncogene overexpression [28]. Inter-origin distances were 
further reduced upon PIF1 depletion in RAS transformed 
fibroblasts, relative to control, (average distance: 
31.26μm vs 47.45μm (p=0.004) in PIF1 or control siRNA 
MRC5SV2-RAS cells, respectively), implying that new 
origin firing was increased to compensate the slow fork 
rates in these cells. By contrast, inter-origin distances were 
unaffected after PIF1 depletion in parental cells (average 
distance: 59.83μm in both PIF1 or control siRNA treated 
MRC5SV2 cells), where a modest reduction of fork speed 
was observed.
In the above assays of parental and RAS-transformed 
cells, we also measured the symmetry of progression of 
sister forks initiated from the same origin (Fig. 2D, E). 
As previously defined [32], we considered symmetric 
progression of the two forks when the ratio of shorter to 
longer IdU track was > 0.75. Replication structures with 
poor symmetry (≤ 0.75) were increased significantly 
upon PIF1-depletion in parental and RAS-transformed 
fibroblasts indicating increased fork stalling. In particular, 
the fold increase of total structures with poor symmetry 
after PIF1 depletion was 1.72 and 2.43 in parental and 
RAS-transformed cells, respectively.
Slower fork rates were also detected in HCT116 
tumour cells (with an activating K-RASG13D mutation) 
following PIF1-depletion [average fork rate: 0.58kb/min 
vs 0.74kb/min (p=0.046) for CIdU tracks and 0.49kb/min 
vs 0.58kb/min (p=0.041) for IdU tracks in PIF1 and 
control siRNA treated HCT116 cells (Fig. 3A-I)]. 
Replication fork progression was restored by induced 
overexpression of a siRNA-resistant recombinant of the 
wild type PIF1, confirming specificity of siRNA treatments 
(Fig. 3A, B and D-F). In particular, in both un-induced 
and tetracyclin-induced cells following treatment with 
control or PIF1 siRNAs, respectively, the average fork rate 
was 0.7kb/min (p=0.332) in CIdU tracks and 0.6kb/min 
(p=0.176) in IdU tracks. In contrast, HCT116 cells 
carrying an inducible PIF1 E307Q helicase mutant (that 
abolished helicase activity while retaining DNA binding 
ability [24], failed to correct fork rates to wild type levels 
after induction [average fork rate: 0.67kb/min vs 0.89kb/
min (p=0.01) of CIdU tracks and 0.52kb/min vs 0.81kb/
min (p=0.02) of IdU tracks in induced cells treated with 
PIF1 siRNA and un-induced cells treated with control 
siRNA, respectively (Fig. 3A, C and G-I)]. However, 
fork rates were weakly increased in PIF1-depleted cells 
conditionally expressing the mutant protein [average fork 
rate: 0.67kb/min vs 0.48kb/min (p=0.01) of CIdU tracks 
and 0.52kb/min vs 0.38kb/min (p=0.05) of IdU tracks 
in PIF1 siRNA treated cells after induction or not of the 
mutant PIF1, respectively. This could potentially be due 
to the annealing activity of the PIF1 helicase that is not 
affected by the E307Q mutation [24].
Taken together, our data show that, during an 
unperturbed cell cycle, PIF1-depletion affects DNA 
replication by slowing fork rates, especially in oncogene-
expressing cells, and by increasing fork stalling. 
Importantly, the function of PIF1 in maintenance of 
replication fork progression requires, its helicase activity.
PIF1 depletion increases fork stalling during 
ligand-induced stabilization of G4-structures
We next investigated whether impairment of fork 
movement upon PIF1 depletion is affected by ligand-
induced stabilization of G4-structures, given the in 
vitro preference of human PIF1 for unwinding these 
structures [25] and, the supporting role of ScPif1 on 
DNA replication through G4-motifs [33]. Modifying 
our previous fibre-assay, non-cancerous fibroblasts 
were sequentially pulsed with CIdU and IdU for 
equal periods of time, but during the second pulse a 
G4-ligand was added (Fig. 4A). We have used two 
different commercially available ligands, the quindoline 
derivative SYUIQ-05 and the berberine derivative 
N-(3-Aminopropyl) piperidine. Both small molecules 
induce formation and stabilisation of G4-structures at 
telomeres [34, 35] as well as at non-telomeric regions 
[36, 37]. Replication slowing upon ligand treatments 
resulted in shortening of the IdU track relative to CIdU 
one. In particular, in the presence of 1μM SYUIQ-05 
or 5μM N-(3-Aminopropyl) piperidine and following 
PIF1-depletion, a significant reduction in fork rates of 
ongoing replication structures was observed, relative 
to control and untreated cells (Fig. 4B), leading to 
a significant increase in the ratio of CIdU/IdU track 
lengths, respectively (Fig. 4C-E). We found that the 
percentage reduction of the fork speed of IdU tracks after 
PIF1 depletion, relative to control, was 27.78% (p=0.016) 
in untreated MRC5SV2 cells and further increased to 
30.64% (p=0.008) and 52.11% (p=0.02) in the presence 
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of 1μM SYUIQ-05 5μM or N-(3-Aminopropyl) 
piperidine, respectively. Importantly, reduced fork 
rates under the above conditions were also observed in 
ongoing replication structures initiated bi-directionally 
during the first pulse-label (Fig. 4F). This excludes the 
possibility that the above effect is due to the function of 
G4-ligands only at telomeres, given that DNA replication 
origins at telomeres are unidirectional [38]. Following 
PIF1 depletion, DNA replication elongation rates 
were reduced 35.13% (p=0.001), relative to control, in 
untreated cells while in the presence of DNA ligands, the 
reduction was 10.20% (p=0.02) and 58.93% (p=0.021) in 
SYUIQ-05 5μM or N-(3-Aminopropyl) piperidine treated 
cells, respectively. The limited effect of SYUIQ-05 on 
fork rates of non-telomeric regions could be explained by 
the preference of this ligand for binding on a particular 
G4-region [36]. However, SYUIQ-05 treatment 
significantly increased the frequency of arrested forks 
in PIF1-depleted cells relative to control (Fig. 4G-I). 
Arrested forks were considered only as replication 
structures which progressed during the first pulse and 
failed to progress during the second. We found that 
upon PIF1 depletion, arrested forks increased 78.02% 
(p=0.007) and 55.16% (p=0.04), relative to control, 
20min or 40min after removal of SYUIQ-05 ligand, 
respectively. Taken together, our data suggest that PIF1 
protects replication forks from stalling during ligand-
induced stabilization of G4-structures.
Figure 2: PIF1 depletion changes the frequencies of activation of new replication origins and fork stalling under 
conditions of oncogene overexpression. (A) Labelling protocol of parental and MRC5SV2-RAS cells (clone 2) after indicated 
treatment, (B) Representative image (scale bars=10μm) of origin-to-origin distance (marked with a white dashed line) in MRC5SV2-RAS 
cells treated with PIF1 siRNAs, (C) Bar graphs with inter-origin distances, (D) Representative images (scale bars=5μm) and, (E) Bar 
graphs with shown percentages of symmetric and asymmetric progression of sister forks initiated from the same origin during the 1st pulse. 
Data bars present the mean of three independent experiments and error bars represent SD. p values of Student’s t test and the exact numbers 
(n) for each experiment are listed as well.
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Depletion of PIF1 differentially affects cell 
growth and survival of parental and  
RAS-oncogene-transformed cells
We next examined how the above defects in 
DNA replication progression impacted overall cellular 
growth, proliferation and survival upon PIF1-depletion. 
Consistent with the effects of PIF1-depletion on 
replication fork progression, FACS-based analysis of 
DNA content in parental fibroblasts, showed a slight 
but significant increase in the percentage of cells in 
S-phase after PIF1-depletion [24.32% vs 21.24% 
(p=0.021) after 48h and 28.7% vs 21.07% (p=0.003) 
after 72h transfection with PIF1 or control siRNAs, 
respectively, (Fig. 5A, B and Supplementary Information 
Table 1)]. This increase in S-phase cells was much more 
Figure 3: Decreased replication rates upon PIF1 depletion were restored in HCT116 cells by overexpression of wild 
type PIF1 protein while a helicase mutant failed to restore replication to wild type levels. (A) Labelling protocol of HCT116 
cell lines (HTREX-wtPIF1 and HTREX-PIF1E307Q) transfected with control or a siRNA duplex targeting a 3’ UTR region of PIF1 
(PIF1 siRNA 2) for 6h before induction of expression of siRNA-resistant recombinant wtPIF1 or mutant PIF1E307Q proteins, respectively. 
Cells left to grow for another 18h before labelling with CIdU and IdU for the indicated time, (B, C) qRT-PCR analysis of total PIF1mRNA, 
relative to U1 snRNA, in HTREX-wtPIF1 and HTREX-PIF1E307Q cells, respectively. (D-I) Distributions and mean values of fork 
rates during both pulses in HTREX-wtPIF1(D-F) and HTREX-PIF1E307Q cell lines (G-I), respectively. Data bars are the mean of three 
independent experiments and (n) the exact number of replication structures measured in each repeat. Error bars represent SD in B-C, F and 
I Panels and SEM in D-E and G-H Panels. P values of Student’s t test are also presented.
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Figure 4: PIF1 protects forks from stalling during ligand-induced stabilization of G4-structures. (A) Labelling protocol of 
MRC5SV2 cells treated with control or PIF1 siRNAs and sequentially labelled with CIdU and IdU in the presence or not of 1μM SYUIQ-5 
or 5μM N-(3-Aminopropyl) piperidine, (B) Bar graphs show mean values of fork rates during IdU pulse, measured as in Figure 3, (C-E) 
Distribution plots of CIdU/IdU ratio, (F) Bar graphs show mean values of fork rates during IdU pulse, measured only in bidirectional 
replication structures (green-red-green), (G) Labelling protocol and, (H) Representative images (scale bars=20μm) of replication structures 
of MRC5SV2 cells treated with control or PIF1 siRNAs and pulsed with CIdU in the presence of 1μM SYUIQ-5. After ligand removal, 
cells were pulsed with IdU for the indicated times, (I) Bar graphs with mean values of arrested forks/termination events, assessed as 
percentage of forks that progressed only during the 1st pulse (red) relevant to all CIdU tracks. Data bars present means of three independent 
experiments and error bars represent SD in B, F, I and SEM in C-E. In CIdU/IdU ratio distributions, the total mean and SD of the three 
repeats are also shown, as well as p values of Student’s t test. The exact numbers (n) of each experiment are listed as well. In panels B 
and F the exact numbers are the same with these in panels C-E. In panel I, n is the number of the total arrested forks pooled from three 
independent experiments and in parenthesis the number of the total CIdU-labelled replication structures (red-green, green-red-green and 
only red) is presented as well.
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pronounced in RAS-transformed fibroblasts, where 
accumulation of cells in S-phase (particularly in early 
S-phase) was evident (relative to control). In particular, 
the percentage of cells in S-phase was 32.52% vs 
20.82% (p=0.008) after 48h and 31.38% vs 21.59% 
(p=0.003) after 72h transfection with PIF1 or control 
siRNAs, respectively. Moreover, co-treatments of 
RAS-transformed fibroblasts with HRAS and PIF1 
siRNAs reduced S-phase populations [%S-phase cells: 
28.24 vs 32.52 (p=0.034) after 48h and 26.82 vs 31.38 
(p=0.039) after 72h co-transfection with PIF1 and 
HRAS siRNAs or single transfection with PIF1 siRNAs, 
respectively]. The above results were also confirmed with 
measurements of BrdU incorporation in asynchronous 
cultures of parental and two different clones of RAS 
transformed fibroblasts treated with two different PIF1 
siRNAs (Supplementary Information Fig. S4).
Furthermore, in MTT proliferation assays, 
metabolic activity nearly doubled over the time course in 
parental cells treated with control or PIF1 siRNAs and in 
RAS-transformed fibroblasts treated with the control siRNA. 
In contrast there was very little increase in activity upon 
PIF1-depletion of RAS-transformed fibroblasts (Fig. 5C). 
Moreover, there was a 10-fold reduction of colony formation 
by PIF1-depleted RAS-transformed fibroblasts relative to 
control or parental fibroblasts (Fig. 5D). These frequencies 
were further suppressed (106- to 180-fold) in PIF1-depleted 
RAS-transformed fibroblasts relative to control or parental 
cells after gemcitabine treatment (Fig. 5D).
Taken together, our data show that, during an 
unperturbed cell cycle, PIF1-depletion has much greater 
impact on the growth, proliferation and survival of 
RAS-transformed cells than on parental fibroblasts.
DNA damage response and integrity of 
replication forks upon PIF1 depletion
We next questioned whether increased fork stalling 
provokes DNA damage response upon PIF1-depletion. 
Intriguingly, immunoblotting analyses showed that in 
normal cycling conditions PIF1-depletion does not trigger 
CHK1 activation, phosphorylation of histone H2AX, or 
hyperphosphorylation of RPA2 in either parental or RAS-
transformed fibroblasts, while ATM phosphorylation 
was at control levels (Fig. 6A, B). Moreover, upon 
disruption of DNA replication with Hydroxyurea (HU) 
treatment, a weak increase of the levels of phosphorylated 
H2AX and ATM was observed in PIF1-depleted cells 
relative to control while CHK1 activation and RPA2 
hyperphosphorylation were largely unaffected. In accord 
with the absence of significant DNA damage response after 
PIF1- depletion, pulse-field gel electrophoresis analyses 
showed similar levels of DSBs in control and PIF1 siRNA 
treated cells in both unperturbed growth conditions or 
after 24h HU treatment (Fig. 6C, D). An increase in DSB 
formation was detected in RAS-transformed fibroblasts 
relative to parental cells, consistent with previous 
reports [39] of induction of replication stress upon RAS 
overexpression. However, this was not further affected 
by PIF1-depletion. The above data imply that there is no 
widespread collapse of replication forks or induction of 
DNA damage upon PIF1-depletion despite the effects of 
PIF1 on DNA replication.
PIF1 promotes recovery of prolonged-disrupted 
DNA replication
Replication stress in oncogene-expressing cells 
depends on DNA precursor deficiency [40], mimicking 
cellular response after treatment with dNTP synthesis 
inhibitors. Based on the hypersensitivity of PIF1-depleted 
tumour cells [26] and RAS transformed fibroblasts to 
such inhibitors, we next investigated the potential role 
of PIF1 on recovery of DNA replication. In parental and 
RAS-transformed fibroblasts we assessed resumption 
of DNA synthesis after HU-induced arrest, using a 
reported assay [41] (Fig. 7A-C): Replication recovery, 
at individual forks, was assessed by the percentage of 
arrest/termination events as well as the percentage of new 
origins that fired during the second pulse. In particular, 
we measured only unilabelled tracks (only red/arrested 
forks and/or only green/new initiation events) which 
had at least 6μm distance between them, as previously 
defined [41]. This type of analysis avoids artifacts due to 
very slow rate of DNA polymerisation during long HU 
treatments [42], which could separate the two labelled 
tracks of a restarting replication fork. We found that upon 
control or PIF1 siRNA transfection followed by 1h HU 
treatment, the percentage of arrested forks in MRC5SV2 
cells was 10.05% vs 6.14% (p=0.056), respectively, while 
in RAS-transformed MRC5SV2 was 11.36% vs 10.64% 
(p=0.421), respectively (Fig. 7D, E). The number of 
arrested forks was increased after 2h HU treatment but 
was not significant different between control and PIF1 
siRNA treated cells, in both lines [22.81% vs 18.34% 
(p=0.119) and 17.11% vs 16.61% (p=0.277) in parental 
and RAS-transformed fibroblasts, respectively].
Taking together, the above data showed that after 
short or prolonged periods of S-phase arrest, the number 
of irreversibly stalled forks after inhibitor removal was 
not significantly affected by PIF1-depletion in either 
of the two cell lines, indicating that replication forks 
remained competent for DNA synthesis at control levels. 
In contrast, the firing of new origins upon PIF1-depletion 
was significantly reduced after 24h HU arrest in parental 
cells [% percentage of IdU pulse initiation events: 57.11 vs 
47.02 (p=0.012) in control and PIF1 siRNA-treated cells, 
respectively (Fig. 7F)] and after 2 and 24h HU arrest in 
RAS-transformed fibroblasts. In particular, following 
control or PIF1 siRNA treatments, the % percentage of 
Oncotarget11389www.impactjournals.com/oncotarget
Figure 5: Differential effects of PIF1 depletion on growth and survival of parental and MRC5SV2-RAS cells 
(clone 2). Cells, after indicated siRNAs treatments, were left to grow for 48 or 72h before harvest for analysis of DNA content by flow 
cytometry. (A) Representative cell cycle profiles and, (B) Bar graphs showing the S-phase cell cycle distributions determined from these 
profiles, (C) Cell proliferation, determined by MTT assays, in parental and RAS-transformed fibroblasts transfected with control or PIF1 
siRNAs. Indicated times correspond to post-transfection hours. Results represent means of at least three independent experiments with 
standard deviations indicated by error bars as well as p values of Student’s t test, (D) Cells treated with indicated siRNAs were plated in 
medium supplied with gemcitabine at increasing concentrations and left to grow. Colonies of surviving cells were scored and are presented 
as surviving curves.
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new origin firing in MRC5SV2-RAS cells during IdU 
pulse was 7.69 vs 5.54 (p=0.025) after 2h HU and 59.36 
vs 30.94 (p=0.002) after 24h HU, respectively (Fig. 7G).
The effects of PIF1-depletion on replication 
recovery after prolonged S-phase arrest were also 
tested by immunofluorescence analysis of parental and 
two different clones of RAS-transformed fibroblasts 
pulse-labelled as above (Fig. 8A-C and Supplementary 
Information Fig. S5A-C). We found that the proportion 
of S-phase cells restarting replication (labelled with both 
CIdU and IdU), was not affected by PIF1-knockdown in 
either of the two cell lines [% percentage of restarting cells 
following control or PIF1 siRNA treatment: 97.41 vs 99.47 
(p=0.268) and 98.49 vs 99.33 (p=0.092) in MRC5SV2 and 
MRC5SV2-RAS cells, respectively, Fig. 8D). Importantly, 
PIF1-knockdown significantly diminished the number 
of new cells entering S-phase (labelled only with IdU) 
in both parental and RAS-transformed lines (Fig. 8E). 
In particular, following PIF1-depletion the percentage 
reduction of new S-phase cells, relative to control cells, 
was 38.49% (p=0.008) in MRC5SV2 and 40.77% 
(p=0.001) in MRC5SV2-RAS cells (clone 2). Similar 
Figure 6: Increased fork stalling after PIF1 depletion is not associated with activation of DNA damage responses, 
or increased DSB formation. (A-B) Immunoblot analysis of phospho-ATM, ATM, phospho-CHK1, CHK1, RPA2 and γ-H2AX in 
total protein extracts and, (C-D) DNA Double-Strand Break (DSB) formation analysis, by Pulse-field Gel Electrophoresis, in parental and 
MRC5SV2-RAS cells (clone 2) transfected with control or PIF1 siRNAs for 48h and treated or not with 2mM HU for indicated times. 
ϐ-actin levels served as loading controls. Parental cells with no siRNA treatment as well as cells irradiated with 2Gy or 10Gy were used as 
negative and positive controls for DSB formation, respectively. DSBs are indicated with an arrow.
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Figure 7: Effects of PIF1-depletion on recovery of stalled replication forks. (A) Labelling protocol and, (B, C) Representative 
images (scale bars=20μm) of replication structures from parental and MRC5SV2-RAS cells (clone 2) treated with control or PIF1 siRNAs. 
White arrows marked with (i) or (ii) indicate arrested forks and new initiation events, respectively, (D, E) Bar graphs of arrested forks/
termination events after indicated HU treatments, measured as in Figure 4, (F, G) New initiation events following the above treatments, 
assessed as second label initiations (only green) relevant to all CIdU tracks, respectively. The mean and SD of three independent experiments 
are shown, as well as p values of Student’s t test. In Panels D, E, (n) represents the total number of CIdU-labelled replication structures (red, 
red-green and green-red-green) pooled from three independent repeats, while in Panels F, G, (n) is the same as in D and E, respectively.
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results were also obtained with a second clone (clone 3) of 
RAS-transformed fibroblasts [% percentage reduction of 
new S-phase cells: 36.32 (p=0.015) and 51.63 (p=0.0001) 
after treatment with PIF1 siRNA1 and PIF1 siRNA2, 
respectively, (Supplementary Information Fig. S5C)].
To examine further how PIF1-depletion affects 
new origin firing in S-phase cells restarting replication, 
we measured active DNA replication foci in single nuclei 
(Fig. 8F and Supplementary Information, video 1). As 
previously defined [43], we considered fired sites of 
replication before HU treatment that remained active and 
after inhibitor removal, the nuclear foci where signals 
from the CIdU (red), and the IdU (green) pulses were 
co-localized (yellow). New replication sites, activated 
after HU arrest, were assessed in each nucleus as the 
number of foci containing only IdU signal normalised 
to the total number of foci containing CIdU signal. We 
found that the percentage of fired replication foci that 
remained active after HU arrest was not affected by 
PIF1-depletion in either of the two cell lines [34.94% vs 
36.11% (p=0.195) in MRC5SV2 and 39.29% vs 41.97% 
(p=0.271) in RAS-transformed MRC5SV2 cells upon 
control or PIF1 siRNA treatments, respectively]. In 
contrast, the percentages of new replication foci that fired 
after HU removal were slightly but significantly reduced 
upon PIF1-depletion only in RAS-transformed cells 
[67.42% vs 57.59% (p=0.033) in control or PIF1 siRNA-
treated cells, respectively], while parental fibroblasts were 
not significantly affected [93.04% vs 81.58% (p=0.162) in 
control or PIF1 siRNA-treated cells, respectively].
Taken together, our data suggest a role for PIF1 in 
recovery of DNA replication. This role can facilitate the 
ability of the cells to resume prolonged-disrupted DNA 
synthesis by affecting firing of new origins and mainly by 
governing the number of new cells entering S-phase.
DISCUSSION
Taken together, we have established a functional role 
for human PIF1 helicase in maintenance of unperturbed 
genome-wide DNA replication fork progression. This 
is the first time that a non-processive DNA helicase is 
reported to support processive DNA synthesis under normal 
cycling conditions in humans. Depletion of PIF1 resulted 
in slower replication fork rates and increased fork stalling 
under normal cycling conditions as well as after ligand-
induced G4-structure stabilization. During replication, fork 
movement can be disrupted by folding of G4-structures 
at ssDNA GC-rich regions of lagging or leading strands 
[44–46]. In accord with PIF1’s protective role against 
accumulation of stalled forks during treatments with DNA 
G4-ligands and evidence for nuclear co-localisation of PIF1 
with binding regions of another G4-ligand [47], we speculate 
that PIF1 facilitates fork progression by directly binding 
and unwinding these secondary structures. This idea is also 
supported by the fact that the percentage reduction in fork 
rate of the whole genome upon PIF1-depletion was further 
increased in the presence of DNA G4-ligands, as we showed 
here. Upon PIF1-depletion, unresolved G4-structures can 
stall the DNA polymerase complex slowing or arresting 
replication forks and threatening genome stability. Increased 
replication stress and unscheduled initiation during oncogene 
overexpression [28] could affect G4-structure formation 
increasing the PIF1-dependence of fork progression, as we 
detected in RAS-transformed cells relative to parental cells. 
The proposed role of human PIF1 is in agreement with the 
reported role of the yeast ScPif1 in replication and stability 
of tandem arrays containing sequences with the potential 
to form G4-structures [48], as well as the highly conserved 
function of the Pif1 family helicases on suppression of 
DNA damage at G4-structures in the yeast genome [9]. 
However, it remains to be proved whether the effect of PIF1 
knockdown on DNA replication progression is restricted to 
G4-regions of the human genome.
Despite the impairment of replication fork 
movement upon PIF1-depletion, cell cycle distributions 
of non-cancerous cells were almost normal, with a 
slight delay in S-phase, and growth and proliferation 
were mainly unaffected. This could be explained by an 
efficient re-priming of replication downstream of paused 
site [49, 50]. By this rationale, the observed increased 
fork stalling upon PIF1-depletion could be considered 
as temporal. This is also supported by the fact that DSB 
formation was not increased upon PIF1-depletion in 
either parental or RAS-transformed cells. By contrast, 
depletion of PIF1 becomes important for DNA replication 
and proliferation under conditions of oncogene-induced 
replication stress: in RAS-transformed lines, fork 
slowing was exacerbated leading to accumulation of 
cells in S-phase. Moreover, insufficient replication was 
accompanied by reduced proliferation rate, which can be 
explained by eventual growth arrest rather than an increase 
in spontaneous apoptosis.
When DNA synthesis is disrupted or damaged, 
restart of DNA polymerization at paused replication 
forks is essential for maintenance of genomic stability 
[51] and depends critically on proteins that stabilize 
forks, such as the BLM [52], WRN [53] and FANCJ/
BACH1[54] helicases, and/or proteins required for 
homologous recombination, such as the RAD51[55, 56]. 
By contrast to the reported role of the above helicases on 
fork stabilization, PIF1 was dispensable for fork restart 
after replication disruption by HU treatment. However, 
when replication forks stall irreversibly, after prolonged 
HU arrest, resumption of replication occurs mainly 
through firing of new origins [41, 57]. We show here 
that PIF1 is required for replication recovery through its 
role in S-phase entry and origin firing at new replication 
sites. This function of PIF1 is redundant in normal 
growth conditions or after short periods of S-phase 
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Figure 8: PIF1 is required for efficient resumption of DNA synthesis after prolonged replication arrest. Cells were 
labelled and treated with HU as indicated in (A) and replication foci were detected in whole nuclei after pre-extraction, fixation and 
immunostaining for CIdU (red) and IdU (green). Single z-sections through representative nuclei of RAS-transformed cells (clone 2) 
resuming DNA synthesis under the above conditions are presented in (B, C) (Scale bars=2.5μm). The three-dimensional image stack for 
the cell in (B) is shown in Supplementary Information, video S1. Cells restarting replication are labelled with both CIdU and IdU and 
their percentages relative to all CIdU-labelled cells are presented in (D). New S- phase cells are labelled only with IdU and are shown as 
percentages of all cells in (E). (F) Bar graphs show the percentage of active replication foci during the different pulses normalised to total 
CIdU labelled foci in each nuclei. Nuclear foci representing replication sites that were active only during the first label (red) are marked 
with (1) in (B), while those that have been activated during the second label (green) are marked with (2). Nuclear foci where red and 
green signals co-localized (yellow), represent replication sites that fired during the first pulse and remained active during the second, after 
HU arrest, are marked with (3). The mean and SD (D, E) or SEM (F) of three independent experiments are shown, as well as p values of 
Student’s t test. In D and E, (n) represents the total number of CIdU-labelled (red and red-green) or total cells (DAPI-stained), respectively, 
while in F, (n) represent the total number of single nuclei pooled from three independent repeats.
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arrest. However, it could become critical when there is 
increased demand for origin firing from new replication 
sites, especially during oncogene-induced replication 
stress [58]. Recently, a consensus G4-motif, that can form 
G4-structure, has been reported to be associated with 
replication origin selection, usage efficiency and timing 
in human cells [59]. Furthermore, the above signature-
motif was found to coincide with the specific RNA/ssDNA 
binding sequence of the human Origin Recognition 
Complex [60]. PIF1 could influence origin-firing 
processes through its ability to resolve such G4-structures 
[46]. In agreement with this mounting evidence, our data 
showed that in parental fibroblast upon PIF1-depletion 
the percentage reduction in fork rate of non-telomeric 
regions (35.13%) is similar to the percentage reduction 
in new S-phase entry (38.49%) suggesting that they may 
be correlated. This proposed function of PIF1 could also 
facilitate the recruitment of replication initiation factors 
to these structured sites. In support of this, reciprocal 
immunoprecipitation of C-terminal-FLAG-tagged PIF1 
and endogenous CDC45 in human cancer cells has been 
reported [61], suggesting that PIF1 associates with the 
essential replication initiation co-factor CDC45 in vivo 
[62]. On the other hand, we cannot exclude an indirect role 
of PIF1 on resumption of DNA replication and S-phase 
entry. We have previously reported an increase in p21 
protein levels upon PIF1 depletion in HCT116 cells [26]. 
However, this increase was detected only in a fraction of 
cells at the G1/S border that were not incorporating BrdU 
during resumption of replication after 24h arrest. Thus, it 
seems unlikely that the observed reduction of the active 
replication sites in RAS transformed cells restarting DNA 
synthesis upon PIF1 depletion is subject to p21 regulation 
although this may affect cells entering S-phase. Further 
studies will define the role of PIF1 on firing of replication 
origins and S-phase entry and whether this is restricted to 
sites with G4-structures.
Collectively, we report a critical role for PIF1 
in the regulation of DNA replication under excessive 
replication stress. It would be interesting in the future to 
investigate whether the dependence of DNA replication 
on PIF1 is increased upon expression of oncogenes other 
than RAS. Moreover, our results of sensitisation of RAS 
transformed cells to gemcitabine upon PIF1 depletion 
warrant further studies of the effects of manipulation of 
PIF1 alone, as well as in combination with replication 
inhibitors or G4-ligands, on the survival of oncogene-
driven tumours in model organisms.
METHODS
Cell lines and cultures
HCT116 cell line was obtained from American 
Type Culture Collection (Manassas, VA, USA). Human 
fibroblast cell line MRC5SV2, a derivative of MRC5 
after transformation with the virus SV40, was obtained 
from the European Collection of Cell Cultures (Porton 
Down, Salisbury, UK). Cell line identity was confirmed 
by DNA fingerprinting (LGC Standards, Teddington, 
UK), and mycoplasma-free status was verified using the 
Mycoplasma PCR ELISA kit (Roche-Applied Biosciences, 
Mannheim, Germany).
HCT116 strains conditionally over-expressing wild 
type or mutant PIF1 proteins were obtained by using 
the Flp-In T-REX system (Invitrogen, Carlsbad, CA, 
USA). Briefly, an HCT116 Flp-In T-REX host cell line 
was generated according to manufacturer’s instructions. 
Full length of the hPif1a coding region, carrying or not 
the E307Q substitution and having or not a FLAG-tag at 
the C-terminus, were cloned into the pcDNA5/FRT/TO 
vector and integrated into the HT-REX cell line via Flp 
recombinase-mediated DNA recombination at the FRT 
site. Tetracyclin inducible stable lines were isolated by 
selection for blasticidin and hygromycin resistance.
MRC5SV2 strains stably over-expressing the mutant 
HRASG12V were generated by transfection of HRASG12V 
cDNA (Addgene plasmid 22252) after subcloning 
into pCAG-Flox vector. Stable isolates expressing 
HRASG12V(clones 2 and 3) were obtained by selection in 
puromycin.
MRC5SV2 and HRASG12V-MRC5SV2 cells used 
in all the experiments were derived from cultures of no 
more than 15 passages and were negative for senescence-
associated β-galactosidase staining (9860; Cell Signaling, 
Danvers, MA, USA).
Cells were maintained in DMEM supplemented 
with 10% fetal bovine serum (FBS). HU, SYUIQ-5 and 
N-(3-Aminopropyl) piperidine (Sigma-Aldrich, St Louis, 
Missouri, USA) were used at a concentration 2mM, 1μM 
and 5μM, respectively. Cells were irradiated using a 
CIS IBL 437 Cs-137 irradiator (CNRS, Gif-Sur-Yvette, 
France).
SiRNA transfection
For HRAS depletion a pool of four siRNA duplexes 
[LQ-004142-00, Dharmacon (Lafayette, CO, USA)] with 
the following sense sequences were used:
GAACCCUCCUGAUGAGAGU, AGACGUGCC 
UGUUGGACAU, GGAAGCAGGUGGUCAUUGA and 
GAGGAUGCCUUCUACACGU. PIF1 siRNAs with 
the sense sequences GGCCAGAGCAUCUUCUUCATT 
(siRNA 1) and CCCUUCAGAGCCUAACCAATT 
(siRNA 2) were obtained from Applied Biosystems 
(Ambion, Carlsbad, CA, USA). Negative Control siRNAs 
with no sequence homology in the human genome, were 
obtained from Eurogentec (OR-0030-NEG, Seraing, 
Liege, Belgium). Lipofectamine 2000 (Invitrogen) was 
used to transfect siRNA duplexes into cells, according to 
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manufacturer’s instructions. The cells were incubated for 
48 hours before further treatment.
Flow cytometry and pulse-field gel 
electrophoresis
Flow cytometry and Pulse-Field Gel Electrophoresis 
have described previously [63]. Further data analysis 
was performed using the FlowJo software (http://www.
flowjo. com).
Protein extraction and western blotting
Whole-cell extracts were prepared, fractionated, 
and blotted onto nitrocellulose (Whatman Schleicher 
and Schuell, Dassel, Germany) as described previously 
[64]. Proteins were detected with the ECL system (GE 
Healthcare, Little Chalfont, UK) and visualized with the 
Fujifilm LAS-3000 imager (Fujifilm, Tokyo, Japan). The 
following specific antibodies were used: ATM (sc- 23921 
Santa Cruz, Dallas, Texas, USA), γH2AX (2577; Cell 
Signaling), CHK1 (2360; Cell Signaling), β-actin (A-5060; 
Sigma-Aldrich), RPA2 (NA19L; Calbiochem, Billerica, 
MA, USA), phospho-ATM (Ser1981) (2152-1; Epitomics, 
Burlingame, CA, USA), phospho-CHK1 (Ser345) (2349; 
Cell Signalling), HRAS (OP38; Calbiochem).
RNA purification and qPCR analysis
Extraction and purification of total RNA, DNase I 
treatment and first-strand cDNA synthesis have described 
previously [26]. qPCR reactions were run on a 7900HT 
Fast Real-Time PCR system (Applied Biosystems) with 
SYBR Green reagents (Quantace, London, UK) and 
0.25 µM of each primer. The following PCR conditions 
were used: Heating for 10 min at 95°C followed by 
amplification for 45 cycles (15sec 95°C / 15sec 59°C 
/ 25sec 72°C). All samples were analysed in duplicate. 
SDS 2.2.1 software (Applied Biosystems) was used for 
data analysis and evaluation. Primer3plus (http://www.
bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) 
and NCBI (http://www.ncbi.nlm.nih.gov/tools/primer-
blast) programs were used to design the following 
primers:
PIF1 (i): 5’ccctggattgtgtggagatt 3’ (Forward);
PIF1 (ii): 5’actccagactgaggctcctg 3’ (Reverse);
PIF1 (iii): 5’cctatgtggccctttctcg 3’ (Forward);
PIF1 (iv): 5’ggtttgggtccatgttctcc 3’ (Reverse);
ATPS6: 5’ccttatgagcgggcacagt 3’ (Forward);
ATPS6: 5’ ccagggctattggttgaatg 3’ (Reverse);
Primers for the U1 snRNA were from Hautbergue, 
G. [65]
DNA-fibre analysis
We have used pulse-labeling conditions that 
support DNA polymerization at normal rates according 
to [31]. Labelled-cells were harvested, lysed and DNA 
spreading, and immunostaining were performed as 
previously described [58]. For CIdU detection, a rat 
anti- Bromodeoxyuridine (BrdU, clone BU1/75(ICR1); 
AbD Serotec) were used in a dilution 1:500 and 
detected with an Alexa-555 conjugated goat anti-rat IgG 
(A-21434; Molecular Probes, Eugene, Oregon, USA). 
For IdU detection, a mouse anti-BrdU [(clone B44); 
BD, Franklin Lakes, NJ, USA] were used in a dilution 
1:500 and detected with an Alexa-488 conjugated 
F(ab’)2 fragment of goat anti-mouse IgG (A-11017; 
Molecular Probes). Antibody dilutions and washes were 
performed in PBS containing 1% BSA and 0.1%Tween 
20. Coverslips were mounted in Fluoroshield medium 
(F6182; Sigma-Aldrich).
Immunodetection of replication sites in whole 
nuclei
Cells were grown on glass coverslips, treated with 
siRNAs and pulse-labelled as described above. Cells 
were pre-extracted with a buffer containing 10mM 
HEPES pH 7.9, 10mM KCI, 1.5mM MgCI2, 0.34M 
sucrose, 10% glycerol, 0.1% Triton X-100 and 1mM 
PMSF for 5min at 4°C, fixed with 3% paraformaldehyde, 
2% sucrose in PBS for 10min at R/T and permeabilized 
with 0.5% Triton X-100 in PBS for 5min at 4°C. 
DNA on coverslips was denaturated with 2N HCI for 
40min at R/T, followed by neutralization with PBS 
buffer. CIdU and IdU signals were detected with the 
antibodies described above. Coverslips were mounted in 
Vectashield medium with 4′,6-Diamidino-2-phenylindole 
dihydrochloride [(DAPI), H-1500; Vector Laboratories 
Inc., Burlingame, CA, USA].
Immunofluorescence analysis
Immunofluorescence at replication structures 
and whole nuclei was visualized using an Olympus 
FV1000 confocal BX61 upright microscope equipped 
with X 60(1.42 NA) or X 100 (1.4 NA) objective lens, 
respectively. Images were captured and analyzed by 
Fluoview 3.1 software (Olympus, Shinjuku, Tokyo, 
Japan). Measurements of labelled tracks were performed 
in micrometres, by using the ImageJ software (http://
rsbweb.nih.gov/ij/), and converted to kilobases with the 
reported(30) factor 1μm=2.59Kb.
For co-localisation experiments, serial optical 
sections of 0.2μm were collected through nuclei using a 
wide-field fluorescence microscope (DeltaVision DV3; 
Applied Precision, Issaquah, WA, USA) equipped with a 
100X (1.4 NA) objective (Olympus). SoftWorx (Applied 
Precision) software was used to deconvolute image stacks, 
which were further analysed with Volocity (Perkin Elmer, 
Waltham, MA, USA) software. Nuclear foci with size 
>0.05 and <1.0μm, labelled with CIdU and/or IdU were 
measured in each cell.
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MTT proliferation assay
Cells seeded at a density of 1,000 cells/well of a 
microplate were transfected the next day with indicated 
siRNAs and left to grow for another 3–5 days. At 
that point, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] reagent (11465007001, 
Roche- Applied Biosciences) was added at a final 
concentration of 1mg/ml followed by incubation at 37°C 
for 3hrs. Solubilization of the produced formazan was 
achieved by sodium dodecyl sulphate (SDS) and further 
incubation at 37°C O/N. Concentration of the soluble 
product was determined by optical density at 540nm, 
using standard microplate absorbance reader.
Statistical analysis
Statistical analysis of the data was performed 
using Student’s t-test from paired samples. P value was 
considered statistically significant when was <0.05. Error 
bars in bar graphs represent the standard deviation in the 
values (SD) or the standard error of the mean (SEM) of at 
least three independent experiments, as stated in Figure 
legends. The exact numbers (n) are listed as well.
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